ARTHEx Biotech doses first patient in Phase I-IIa trial of ATX-01 for Myotonic Dystrophy Type 1, targeting microRNA 23b.
Read more
Nurix Therapeutics' BTK degrader NX-5948 shows 77.8% response rate in Phase 1 trial for Waldenstrom’s Macroglobulinemia.
Read more
Nektar's NKTR-255 combined with CAR-T therapy shows doubled 12-month relapse-free survival in B-cell Acute Lymphoblastic Leukemia patients.
Read more
Teleflex's Barrigel™ rectal spacer shows safety and efficacy in reducing rectal radiation exposure during Prostate Cancer therapy, as presented at ASTRO 2024.
Read more
Noema Pharma's NOE-105 (gemlapodect) meets all endpoints in Phase 2a trial for Tourette Syndrome, showing significant tic reduction and no serious adverse events.
Read more
Factor Bioscience and Eterna Therapeutics partner to advance cell therapies for Oncology, Autoimmune, and Rare Diseases.
Read more
PatchRx and Optimize Health partner to enhance remote monitoring for chronic conditions, improving medication adherence and reducing healthcare costs.
Read more
Tonix Pharmaceuticals receives initial payment from U.S. Department of Defense for $34 million contract to develop broad-spectrum antivirals.
Read more
Sanofi and Orano Med partner to develop next-generation radioligand therapies for rare cancers using lead-212 isotopes.
Read more
Novocure's Tumor Treating Fields receives FDA approval for metastatic Non-Small Cell Lung Cancer, marking a significant survival improvement.
Read more
Valneva and LimmaTech's tetravalent Shigella vaccine candidate receives FDA Fast Track designation to expedite development for Shigellosis.
Read more
Theriva Biologics' VCN-01 receives orphan medicinal product designation from the European Commission for Retinoblastoma treatment.
Read more
FDA approves Astellas' VYLOY™ (zolbetuximab-clzb) for first-line treatment of advanced gastric and gastroesophageal junction adenocarcinoma with CLDN18.2-positive tumors.
Read more
Glaukos' Epioxa achieves primary efficacy endpoint in Phase 3 trial for Keratoconus, supporting upcoming FDA submission.
Read more
Merck's CAPVAXIVE™ shows strong immune response in Phase 3 trial for adults at risk of Pneumococcal Disease.
Read more
Rosalind Franklin University receives $100,000 grant to study molecular mechanisms in metastatic Breast Neoplasms.
Read more
Monopar files a provisional patent for new radiopharmaceutical linkers, enhancing stability and biodistribution for cancer treatment.
Read more
The Michael J. Fox Foundation launches LITE to accelerate LRRK2-targeted therapies and biomarkers for Parkinson's Disease.
Read more
Terray Therapeutics secures $120M in Series B funding to advance AI-driven small molecule drug development and immunology programs.
Read more
SONIRE's HIFU therapy system receives FDA Breakthrough Device designation for Pancreatic Neoplasms treatment.
Read more
The National Kidney Foundation invests in Revalia Bio to advance personalized therapies for Chronic Kidney Disease using human organ data.
Read more
OmniaBio opens Canada's largest cell and gene therapy manufacturing facility, enhancing access to advanced treatments and employing AI for efficiency.
Read more
AscellaHealth acquires CHAPPER healthcare to expand global specialty pharmaceutical distribution and enhance market access.
Read more
Kexing Biopharm launches Apexelsin® in the EU market at CPHI Milan 2024, marking a significant step in its global anti-cancer strategy.
Read more
Nurix Therapeutics appoints Anil Kapur to its board, enhancing commercialization strategy for NX-5948 in B-cell malignancies.
Read more
